U.S. Markets close in 2 hrs 5 mins

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Ezekiel J. Emanuel
Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

How is it that pharmaceutical companies can charge patients $100,000, $200,000, or even $500,000 a year for drugs—many of which are not even curative? Abiraterone, for instance, is a drug used to treat metastatic prostate cancer. The Food and Drug Administration initially approved it in 2011 to treat patients who failed to respond to previous chemotherapy.